Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Silo Pharma (Nasdaq: SILO) announced a private placement under Nasdaq at-the-market rules to issue 619,965 shares (or pre-funded warrants) at $6.452 per share, with Series A-3 and short-term Series A-4 warrants exercisable immediately. Gross proceeds are expected at about $4.0M, with up to about $7.7M more if warrants are fully exercised. Proceeds will fund working capital and general corporate purposes.
How this was made
The 30-second read
Why it matters
The company’s at-the-market private placement plus warrant package provides defined gross proceeds but introduces dilution and potential overhang from warrant-related supply; the market will likely focus on closing timing and any implied runway extension.
Market read
A priced equity and warrant financing with immediate exercisability is a concrete, time-sensitive catalyst that can move the stock around closing and in subsequent sessions as dilution expectations update.
What to watch
Warrant terms (exercise price $6.21, immediate exercisability, short-term A-4 expiring 18 months) can drive trading dynamics depending on whether investors view warrant exercise as likely or if the stock trades below/above key strike levels.
Background
Silo Pharma is a developmental-stage biopharmaceutical company with programs including SPC-15 (PTSD) and SP-26 (fibromyalgia/chronic pain).
Ticker impact
Silo Pharma announced a private placement priced at-the-market under Nasdaq rules, selling 619,965 shares plus immediate-exercisable warrants.
Near-term downside bias on dilution risk, with potential volatility around closing and any warrant exercise signals.
The article discloses a priced equity issuance with immediate warrant exercisability and defined gross proceeds, which typically increases supply and can weigh on the stock absent offsetting catalysts.
Market effects
Adds to the ongoing pattern of developmental-stage biotech using warrant-linked financings to fund working capital.
Primarily impacts US small-cap biotech sentiment and Nasdaq-listed microcap liquidity.
Limited direct global spillover; mostly affects US biotech capital markets pricing.
Counterpoint
If the company’s cash runway meaningfully extends into upcoming clinical or regulatory milestones, the dilution overhang may be partially offset by reduced financing risk.
Key entities
- issuerSilo Pharma, Inc.
Nasdaq-listed developmental-stage biopharmaceutical company announcing the private placement and warrant terms.
- placement_agentH.C. Wainwright & Co.
Exclusive placement agent for the offering.
